Cullinan Therapeutics, Inc. CGEM 深 滬
等待開盤 02-05 09:30:00 美东时间
12.16
-1.050
-7.95%
華盛通- 最 高13.3776
- 今 開13.32
- 成交量 37.03万股
- 最 低 12.10
- 昨 收 13.21
- 總市值 7.18亿
- 52周最高 13.43
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 5.68
- 委 比 75.80%
- 總股本 5907.63万
- 歷史最高 59.85
- 量 比 0.83
- 振 幅 9.67%
- 歷史最低 5.68
- 每 手 1
- 風險率 1.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30
Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $30.
02-02 22:33
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $26 to $27.
01-09 00:42
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook
An announcement from Cullinan Management ( ($CGEM) ) is now available. On Janua...
01-08 20:49
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Cullinan Therapeutics Presents Promising CLN-049 Data
Cullinan Management ( ($CGEM) ) has issued an announcement. On December 8, 2025...
2025-12-08 23:57
Cullinan Therapeutics Reports CLN-049 Monotherapy Efficacy With Multiple Complete Responses And Durable Activity In Heavily Pretreated R/R AML Patients, Achieves 31% CR/CRh At Highest Dose, Demonstrates Favorable Safety Across Doses; Phase 1 Data Presented At ASH 2025
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML31% CR/CRh rate
2025-12-08 23:35
Cullinan Therapeutics Says FDA Granted Fast Track Designation To CLN-049 For Treatment Of Relapsed/Refractory Acute Myeloid Leukemia
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patientsCAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE)
2025-12-01 20:14
美股牛股 | OSCR大涨超22%，白宫计划延长奥巴马医改补贴；加密财库公司BitMine大涨19.6%
OSCR大涨超22%，白宫计划延长奥巴马医改补贴；加密财库公司BitMine大涨19.6%，持有3%的ETH代币供应量>>
2025-11-25 15:10
